Quadrosilan

Source: Wikipedia, the free encyclopedia.
Quadrosilan
Clinical data
Trade namesCisobitan
Other namesQuadrosilane; KABI-1774; 2,6-cisdiphenylhexa-
methylcyclotetrasiloxane
Drug classNonsteroidal estrogen
Identifiers
  • 2,2,4,6,6,8-hexamethyl-4,8-diphenyl-1,3,5,7,2,4,6,8-tetraoxatetrasilocane
JSmol)
  • C[Si]1(O[Si](O[Si](O[Si](O1)(C)C2=CC=CC=C2)(C)C)(C)C3=CC=CC=C3)C
  • InChI=1S/C18H28O4Si4/c1-23(2)19-25(5,17-13-9-7-10-14-17)21-24(3,4)22-26(6,20-23)18-15-11-8-12-16-18/h7-16H,1-6H3
  • Key:ZTQZMPQJXABFNC-UHFFFAOYSA-N

Quadrosilan (

organosilicon compound, and is also known as 2,6-cisdiphenylhexamethylcyclotetrasiloxane.[3][5] Quadrosilan has estrogenic activity equivalent to that of estradiol,[6] and can produce feminization and gynecomastia as side effects in male patients.[7][8]

See also

References

  1. ISBN 978-1-4757-2085-3
    .
  2. ISBN 978-94-011-4439-1
    .
  3. ^
    PMID 6346476
    .
  4. PMID 3887539
    .
  5. ISBN 978-0-471-91993-3
    .
  6. S2CID 26669175
    .
  7. ISBN 978-1-4613-4020-1
    .
  8. PMID 345431
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Quadrosilan&oldid=1161900568"